

Table I. Patient characteristics (n=32).

Characteristic	Number of patients (%)
Gender	
Male	25 (78)
Female	7 (22)
Age (years): Median (range)	60 (30-74)
ECOG PS	
0	19 (59)
1	9 (28)
2	4 (13)
Type of lesion	
Unresectable	12 (38)
Recurrence	10 (31)
Residual	10 (31)
Histology	
Intestinal	12 (38)
Diffuse	20 (63)
Prior chemotherapy	
None	20 (63)
1 regimen	8 (25)
2 regimens	3 (9)
3 regimens	1 (3)

ECOG PS: Eastern Cooperative Oncology Group performance status.

hepatic metastases, 60.9% (3/5) for lung metastases and 73.3% (11/15) for peritoneal lesions.

Survival time. The MST after combined S-1/low-dose P therapy was 12.0 months (95% CI 8.9-15.1 months) and the one-year survival rate was 48.2% (95% CI 30.3-66.0%) (Figure 1).

Adverse events. The incidence of adverse events for the entire population was 56.3% (18/32). Grade 3 or greater adverse events were seen in 5 (15.6%) of the 32 patients. The major grade 3 or greater adverse events were thrombocytopenia (12.5%) and renal dysfunction (3.1%), as shown in Table IV.

Discussion

We treated 32 patients with S-1/low-dose P therapy to evaluate its usefulness against advanced and recurrent gastric cancer, and the results showed a better response rate (78.1%) and MST (12.0 months) than with conventional FP therapy. The conventional low-dose FP therapy requires continuous 24-hour infusion of 5-FU, and this requirement can be eliminated by S-1/low-dose P therapy, in which 5-FU is replaced by an oral preparation (S-1). This regimen is simple and there are fewer complications than with the conventional method. Patients' compliance with therapy is improved by substituting S-1/low-dose P therapy for low-dose FP therapy.

Table II. Response to S-1/low-dose P therapy.

	CR	PR	SD	PD	Response rate	95% C.I.
All Patients	1	24	5	2	78.1% (25/32)	61.2-89.0
Prior chemotherapy						
No	1	15	3	1	80.0% (16/20)	58.4-91.9
Yes	0	9	2	1	75.0% (9/12)	46.8-91.1

CR: Complete response, PR: partial response, SD: stable disease, PD: progressive disease; C.I.: confidence interval.

Table III. Response to S-1/low-dose P therapy by evaluable lesions.

Site of lesion	CR	PR	NC	PD	Response rate
Primary	0	5	0	0	100.0% (5/5)
Intraperitoneal lymph nodes	1	11	3	0	80.0% (12/15)
Liver	1	7	4	0	66.7% (8/12)
Lung	0	3	2	0	60.0% (3/5)
Peritoneum	0	11	2	2	73.3% (11/15)
Bone	0	1	3	0	25.0% (1/4)
Other	0	5	1	0	83.3% (5/6)

CR: Complete response, PR: partial response, NC: no change, PD: progressive disease.

Table IV. Adverse events associated with S-1/low-dose P therapy.

Adverse event	Grade*				Incidence of grade 3-4	
	1	2	3	4	n	Percentage
Hematological						
Leukocytopenia	0	1	0	0	0	0%
Anemia	0	3	0	0	0	0%
Thrombocytopenia	0	1	4	0	4	12.5%
Non-hematological						
Nausea/vomiting	4	3	0	0	0	0%
Diarrhea	0	2	0	0	0	0%
Liver dysfunction	0	0	0	0	0	0%
Renal dysfunction	0	0	1	0	1	3.1%
Fatigue	2	1	0	0	0	0%

*National Cancer Institute common toxicity criteria version 2.0.

Koizumi *et al.* (16) recommended the following dosing regimen for S-1 combined with cisplatin therapy for advanced gastric cancer based on the results of phase I and II clinical studies: S-1 for 3 weeks (80 mg/m²/day) followed by a 2-week drug-free period, and cisplatin on day 8 at a dose level of 60 mg/m². They obtained a high response rate of 73.7% (14/19) with this regimen. Hyodo *et al.* (17) reported a regimen suitable for use in outpatient clinics in which S-1 is administered for 2 weeks at a dose level of 70 mg/m²/day.




Figure 1. Overall survival of patients following S-1/low-dose P therapy.

followed by a one week drug-free period, and cisplatin is administered on day 1 and day 8 at a dose level of 20 mg/m^2 ; they reported a response rate of 61.1% with this regimen. Iwase *et al.*, in an attempt to reduce nausea and vomiting caused by cisplatin, also developed a regimen including 24-hour continuous infusion of this agent, but reported a response rate of 50% with a 10% incidence of grade 3 or greater nausea and vomiting (18).

The combined regimen of S-1 daily and low-dose twice-weekly cisplatin in the present study enabled highly effective and safe therapy that is suitable for use in outpatient clinics. Although phase I and II clinical studies of S-1 combined with taxane (19) or CPT-11 (20) have also been conducted, their results were no better than those yielded by S-1 plus cisplatin therapy. The favorable results of S-1 combined with cisplatin seem to be explained by the synergistic activity between 5-FU and cisplatin based on the theory of biochemical modulation (21, 22). The antitumor activity of 5-FU has been reported to be reinforced particularly markedly when combined with frequent low-dose cisplatin (23). This may explain the fact that the response rate in the previously treated cases was comparable to that in the cases that had never been treated. Furthermore, based on the results of a study comparing the pharmacokinetics of 5-FU in S-1 therapy ($80 \text{ mg/m}^2/\text{day}$) and continuous intravenous

infusion of 5-FU ($250 \text{ mg/m}^2/\text{day}$) it was reported that the AUC_{0-10h} for oral S-1 was 1.9 times higher than that of 5-FU administered by intravenous infusion (9). This may explain why S-1/low-dose P therapy had much greater antitumor activity than low-dose FP therapy. This greater antitumor activity may have contributed to the present high response rate in the previously treated cases.

Koizumi *et al.* (16) reported finding that grade 3 or greater adverse events following S-1 combined with high-dose cisplatin therapy consisted of hematological adverse reactions in 16.0% of all patients, anorexia in 26.0% and nausea in 16.0%. Comparison of the results reported by Koizumi *et al.* and the results of the present study shows that the toxicological profile of high-dose cisplatin therapy seems to differ slightly from that of S-1/low-dose P therapy because gastrointestinal toxicities were observed less frequently in our study.

The problems associated with outpatient chemotherapy with oral anticancer agents include variable patient compliance with the dosing instructions, the development of adverse events, and frequent difficulty in completing therapy as scheduled. Outpatient drug therapy was possible in 31 (96.9%) of the 32 patients in the present study and it was possible to complete therapy without the development of any adverse events in all but one patient. In this last

patient, the serum creatinine level increased to 1.4 mg/dl, suggesting mild compromise of renal function immediately prior to the start of the 5th cycle of treatment, and was accompanied by grade 4 thrombocytopenia and grade 3 renal and hepatic dysfunction. Combined S-1 and cisplatin therapy seems to be associated with a rise in the blood 5-FU level and an elevated risk of 5-FU toxicity for the following reasons: (i) cisplatin is a nephrotoxic drug; (ii) CDHP, a component of S-1, is excreted by the kidneys; and (iii) the serum concentration of CDHP (a DPD inhibitor) may increase. In this light, greater caution should be exercised when using combined S-1 and cisplatin therapy in renally compromised patients.

Reflecting recent phase III results in unresectable advanced and recurrent gastric cancer (24, 25), the standard regimen in Japan is shifting toward combined S-1 and cisplatin therapy.

In the S-1 and cisplatin regimen used in this study, cisplatin was administered in divided doses at a low dose level. When administered in this way, hydration is unnecessary, and even if renal function does become compromised during treatment, it is easy to reduce the dose level of cisplatin or discontinue it altogether. In this respect, this regimen is more favorable from the viewpoint of preventing adverse events than regimens involving the administration of high dose levels of cisplatin.

Conclusion

In conclusion, based on the high response rate, possibility of administration on an outpatient basis and the high quality of life of the patients, combined S-1/low-dose P therapy is considered to offer promise for the treatment of advanced and recurrent gastric cancer. The therapy deserves further evaluation, including its usefulness as second-line therapy for gastric cancer patients.

Acknowledgements

We are grateful to Ito Kawamura, Fumie Ono, Mitsu Nagasaki, Jyunko Kawashima, Hisano Ikeda, Nobuko Tajiri, Kunimasa Nakahashi, Yasunobu Yumura and Hideki Ohue for gathering and preparing data for this study. Since this study was performed as ordinary clinical practice, its cost was covered by National or other insurance. No special funds were needed.

References

- Heidelberger C, Shaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Plevin E and Scheiner J: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. *Nature* 179: 663-666, 1957.
- Nakajima T: Gastric cancer treatment guidelines in Japan. *Gastric Cancer* 5: 1-5, 2002.
- Chung Y, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low-dose cisplatin infusion for treatment of advanced and recurrent gastric adenocarcinomas. *Cancer* 80: 1-7, 1997.
- Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K and Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. *Anticancer Res* 23: 1891-1897, 2003.
- Kobayashi K, Tsuji A, Morita S, Horimi T, Shirasaka T and Kanematsu T: A phase II study of LFP therapy (5-FU (5-fluorouracil) continuous infusion (CVI) and low-dose consecutive (cisplatin) CDDP) in advanced biliary tract carcinoma. *BMC Cancer* 6: 121-131, 2006.
- Tsuji A, Morita S, Horimi T, Takasaki M, Takahashi I and Shirasaka T: Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. *Gan To Kagaku Ryoho* 27(Suppl 2): 528-534, 2000 (In Japanese.)
- Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. *Anticancer Drugs* 7: 548-557, 1996.
- Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. *Cancer Res* 53: 4004-4009, 1993.
- Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T and Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. *Clin Cancer Res* 5: 2000-2005, 1999.
- Maehara Y: S-1 in gastric cancer: a comprehensive review. *Gastric Cancer* 6(Suppl 1): 2-8, 2003.
- Shirasaka T, Yamamitsu S, Tsuji A and Taguchi T: Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. *Invest New Drugs* 18: 315-329, 2000.
- Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T and Hirakawa K: Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). *Clin Cancer Res* 10: 1664-1669, 2004.
- Rai K, Tsuji A, Morita S, Horimi T, Takamatsu M, Takahashi I and Shirasaka T: Continuous infusion of 5-FU and low-dose consecutive CDDP therapy in advanced hepatocellular carcinoma: a phase II study [abstract]. *Proc Am Soc Clin Oncol* 21: 655, 2002.
- Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English edition. Tokyo, Kanehara, pp. 10-24, 1998.
- National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria Manual, Common Toxicity Criteria, Version 2.0 June 1, 1999.
- Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shiro K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. *Br J Cancer* 89: 2207-2212, 2003.

- 17 Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H and Kurita A: A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. *Eur J Cancer* 39: 2328-2333, 2003.
- 18 Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Sugihara M, Ina K, Kusugami K and Goto S: A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. *Anticancer Res* 25: 1297-1302, 2005.
- 19 Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. *Cancer Therapy* 12: 3402-3407, 2006.
- 20 Takiuchi H, Narahara H, Tsujinaka T, Gotoh M, Kawabe S, Katsu K, Iishi H, Tatsuta M, Fujitani K, Furukawa H, Taguchi T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer. *Jpn J Clin Oncol* 35: 520-525, 2005.
- 21 Scanlon KJ, Newman EM, Lu Y and Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. *Proc Natl Acad Sci USA* 83: 8923-8925, 1986.
- 22 Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models *in vivo*. *Cancer chemother Pharmacol* 32: 167-172, 1993.
- 23 Araki H, Fukushima M, Kamiyama Y and Shirasaka T: Effect of consecutive lower-dose cisplatin in enhancement of fluorouracil cytotoxicity in experimental tumor cells *in vivo*. *Cancer Lett* 160: 185-191, 2000.
- 24 Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A and Ohtsu A; Gastrointestinal Oncology Study Group/ Japan Clinical Oncology Group: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) [abstract]. *J Clin Oncol* 25: LBA4513, 2007.
- 25 Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group: Randomized phase III study of S-1 alone versus S-1 plus cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial): S-1 plus cisplatin vs. S-1 in RCT in the treatment for stomach cancer [abstract]. *J Clin Oncol* 25: 4514, 2007.

Received November 20, 2007

Revised January 21, 2008

Accepted February 6, 2008